Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

194 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
PPT1 inhibition enhances the antitumor activity of anti-PD-1 antibody in melanoma.
Sharma G, Ojha R, Noguera-Ortega E, Rebecca VW, Attanasio J, Liu S, Piao S, Lee JJ, Nicastri MC, Harper SL, Ronghe A, Jain V, Winkler JD, Speicher DW, Mastio J, Gimotty PA, Xu X, Wherry EJ, Gabrilovich DI, Amaravadi RK. Sharma G, et al. Among authors: gimotty pa. JCI Insight. 2022 Oct 24;7(20):e165688. doi: 10.1172/jci.insight.165688. JCI Insight. 2022. PMID: 36278493 Free PMC article. No abstract available.
Long-term outcomes to neoadjuvant pembrolizumab based on pathological response for patients with resectable stage III/IV cutaneous melanoma.
Sharon CE, Tortorello GN, Ma KL, Huang AC, Xu X, Giles LR, McGettigan S, Kreider K, Schuchter LM, Mathew AJ, Amaravadi RK, Gimotty PA, Miura JT, Karakousis GC, Mitchell TC. Sharon CE, et al. Among authors: gimotty pa. Ann Oncol. 2023 Sep;34(9):806-812. doi: 10.1016/j.annonc.2023.06.006. Epub 2023 Jul 4. Ann Oncol. 2023. PMID: 37414215 Free PMC article. Clinical Trial.
Upregulation of exosome secretion from tumor-associated macrophages plays a key role in the suppression of anti-tumor immunity.
Zhong W, Lu Y, Han X, Yang J, Qin Z, Zhang W, Yu Z, Wu B, Liu S, Xu W, Zheng C, Schuchter LM, Karakousis GC, Mitchell TC, Amaravadi R, Flowers AJ, Gimotty PA, Xiao M, Mills G, Herlyn M, Dong H, Mitchell MJ, Kim J, Xu X, Guo W. Zhong W, et al. Among authors: gimotty pa. Cell Rep. 2023 Oct 31;42(10):113224. doi: 10.1016/j.celrep.2023.113224. Epub 2023 Oct 8. Cell Rep. 2023. PMID: 37805922 Free PMC article.
Association of oropharyngeal cancer recurrence with tumor-intrinsic and immune-mediated sequelae of reduced genomic instability.
Sannigrahi MK, Raghav L, Rich DJ, Schrank TP, Califano JA, Lukens JN, Sun L, Morgan IM, Cohen RB, Lin A, Liu X, Brown EJ, You J, Mirabello L, Mishra SK, Shimunov D, Brody RM, Pearson AT, Gimotty PA, Diab A, Jalaly JB, Basu D. Sannigrahi MK, et al. Among authors: gimotty pa. bioRxiv [Preprint]. 2024 Nov 4:2024.10.31.621311. doi: 10.1101/2024.10.31.621311. bioRxiv. 2024. PMID: 39574723 Free PMC article. Preprint.
Dietary pro-oxidant therapy by a vitamin K precursor targets PI 3-kinase VPS34 function.
Swamynathan MM, Kuang S, Watrud KE, Doherty MR, Gineste C, Mathew G, Gong GQ, Cox H, Cheng E, Reiss D, Kendall J, Ghosh D, Reczek CR, Zhao X, Herzka T, Špokaitė S, Dessus AN, Kim ST, Klingbeil O, Liu J, Nowak DG, Alsudani H, Wee TL, Park Y, Minicozzi F, Rivera K, Almeida AS, Chang K, Chakrabarty RP, Wilkinson JE, Gimotty PA, Diermeier SD, Egeblad M, Vakoc CR, Locasale JW, Chandel NS, Janowitz T, Hicks JB, Wigler M, Pappin DJ, Williams RL, Cifani P, Tuveson DA, Laporte J, Trotman LC. Swamynathan MM, et al. Among authors: gimotty pa. Science. 2024 Oct 25;386(6720):eadk9167. doi: 10.1126/science.adk9167. Epub 2024 Oct 25. Science. 2024. PMID: 39446948
Divergent effects of acute and chronic PPT1 inhibition in melanoma.
Crissey MAS, Versace A, Bhardwaj M, Jain V, Liu S, Singh A, Beer LA, Tang HY, Villanueva J, Gimotty PA, Xu X, Amaravadi RK. Crissey MAS, et al. Among authors: gimotty pa. Autophagy. 2024 Sep 19:1-13. doi: 10.1080/15548627.2024.2403152. Online ahead of print. Autophagy. 2024. PMID: 39265628
Tumor-Infiltrating Lymphocytes in Necrotic Tumors after Melanoma Neoadjuvant Anti-PD-1 Therapy Correlate with Pathologic Response and Recurrence-Free Survival.
Ma KL, Mitchell TC, Dougher M, Sharon CE, Tortorello GN, Elder DE, Morgan EE, Gimotty PA, Huang AC, Amaravadi RK, Schuchter LM, Flowers A, Miura JT, Karakousis GC, Xu X. Ma KL, et al. Among authors: gimotty pa. Clin Cancer Res. 2024 Nov 1;30(21):4987-4994. doi: 10.1158/1078-0432.CCR-23-3775. Clin Cancer Res. 2024. PMID: 39248505
Corrigendum to 'Long-term outcomes to neoadjuvant pembrolizumab based on pathological response for patients with resectable stage III/IV cutaneous melanoma': [Annals of Oncology 34 (2023) 806-812].
Sharon CE, Tortorello GN, Ma KL, Huang AC, Xu X, Giles LR, McGettigan S, Kreider K, Schuchter LM, Mathew AJ, Amaravadi RK, Gimotty PA, Miura JT, Karakousis GC, Mitchell TC. Sharon CE, et al. Among authors: gimotty pa. Ann Oncol. 2024 Aug;35(8):756. doi: 10.1016/j.annonc.2024.03.002. Epub 2024 Apr 13. Ann Oncol. 2024. PMID: 38614876 Free PMC article. No abstract available.
194 results